Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 6,018 Shares

Key Points

• Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares at an average price of $50.35, generating $303,006.30. The Rule 10b5-1 transaction reduced his holdings by 13.67% to 38,000 shares.
• ELVN shares fell 1.2% to $48.87, while the company reported a quarterly loss of $0.49 per share, missing analysts’ $0.39-per-share loss estimate.
• Institutional investors own 95.08% of the stock, and analysts maintain a generally positive outlook with a “Moderate Buy” consensus and an average price target of $75.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,018 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company's stock, valued at $1,913,300. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total value of $352,534.44.
• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52.

Enliven Therapeutics Stock Down 1.2%

ELVN traded down $0.58 during trading on Monday, hitting $48.87. 2,281,264 shares of the company traded hands, compared to its average volume of 1,268,609. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The stock's fifty day moving average is $56.43 and its 200 day moving average is $46.17. The firm has a market cap of $3.58 billion, a P/E ratio of -29.26 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. BlackRock Inc. bought a new stake in shares of Enliven Therapeutics during the second quarter valued at about $221,255,000. First Light Asset Management LLC grew its stake in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock valued at $69,058,000 after acquiring an additional 1,158,883 shares in the last quarter. Siren L.L.C. purchased a new position in Enliven Therapeutics during the first quarter valued at approximately $29,252,000. Jupiter Topco LLC bought a new stake in Enliven Therapeutics during the 2nd quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ELVN shares. Guggenheim decreased their target price on Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. HC Wainwright upped their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, July 9th. The Goldman Sachs Group increased their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 price objective for the company. Finally, Mizuho boosted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $75.00.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.